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Abstract
Background: The study was designed to investigate immunocompetence in relation to cancer
progression in rat and to assess the effect of the traditional Chinese anti-cancer medicine,
"Shenyang" prescription, on immunity.
Methods: 4-Nitroquinoline-1-oxide (4NQO) was administered to 80 Sprague-Dawley (SD) rats
via the drinking water for up to 36 weeks. Tongue squamous cell carcinoma (SCC) was confirmed
by pathological examination in 61 rats. "Shenyang" prescription was administered to subgroups of
these rats, and blood samples were taken before and after treatment. Lymphocyte subsets were
determined by flow cytometry. Serum Th1 and Th2-type cytokines were assessed by an enzyme-
linked immunosorbent assay.
Results:  As the cancer progressed at the tongue root, the percentage of CD3+CD4+ T
lymphocytes and NK cells and the levels of IFN-γ and IL-2 decreased gradually, while the percentage
of CD3+CD8+ T lymphocytes and the levels of IL-4 and IL-10 increased. The CD4+/CD8+ ratios
were lower in the cancer groups than in the control group. However, after administering
"Shenyang" prescription, the levels of CD3+CD4+ T lymphocytes, NK cells, IFN-γ and IL-2
increased, while the CD3+CD8+ T lymphocyte counts and the levels of IL-4 and IL-10 decreased.
Conclusion: 4NQO-induced lesions were good models for exploring oral cavity carcinogenesis.
The rats with 4NQO-induced SCC demonstrated abnormalities in lymphocyte subsets and a shift
from Th1-type to Th2-type, which were good models for assessing the effect of anticancer agent
on immunity. Oral cancer progression was associated with an aggressive disturbance of immune
function. "Shenyang" prescription has the ability to improve the disturbance of immune function.
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Background
Oral cancer is a major global public health problem, caus-
ing high morbidity and mortality that have not improved
in decades [1]. Squamous cell carcinomas (SCCs) are the
most common type of oral cancer. Although new opera-
tive techniques and adjuvant measures such as chemo-
therapy and radiotherapy against oral SCCs have
progressed, patients with advanced oral SCCs still have a
poor prognosis, with a 5-year survival rate of 65% [2].
Among patients with early stage cancers (I and II), about
30% cannot be cured, while for patients with advanced
stage tumors (III and IV) this percentage may be as high as
70% [3]. To develop new methods and improve existing
protocols for diagnosis and treatment, an animal model
that mimics the natural course of SCCs was mandatory.
Application of 4-nitroquinoline-1-oxide (4NQO) to rat
tongues is a reliable procedure for inducing oral SCCs [4].
4NQO, a water-soluble quinoline derivative, has been
extensively investigated and is known to cause the forma-
tion of DNA adducts. In bacteria, 4NQO induces base-
pair changes (GC→AT) and deletion mutations. This
mutagenic action requires the conversion of 4NQO to 4-
hydroxyaminoquinoline-1-oxide, which binds covalently
to nucleic acids and damages chromosomes [5,6]. In
eukaryotic cells, 4NQO induces diplochromosomes,
indicative of disturbed chromosome replication. 4NQO is
a powerful carcinogen in several organs, and it can specif-
ically induce tongue SCC when applied in low concentra-
tions via drinking water. The resulting sequential changes
and morphological features resemble those seen during
the progression of human tongue squamous cell malig-
nancy. Therefore, 4NQO-induced rat tongue SCC is an
excellent model for studying early events in oral carcino-
genesis.
Our previous clinical research showed that "Shenyang", a
traditional Chinese medicine prescription made mainly
from Radix codonopsitis, Radix astragali, Salvia miltiorrhiza
and Glossy privet fruit, increases the post-operative survival
rate of patients with oral SCCs and the mechanism of
action may involve stimulation of the patient's immune
function [7]. The main active constituents in Radix codo-
nopsitis are tangshenoside and atractylenolide, astragalus
glucans and flavonoids in Radix astragali, tanshinones and
cryptotanshinone in Salvia miltiorrhiza, nuzhenide and
olenropein in Glossy privet fruit. Their pharmacological
actions include effect on immune function, enhancement
in SOD activity, increase in white cell count, liver protec-
tion, and hypoxia tolerance. There is compelling evidence
that immune responses are impaired in patients with oral
SCCs. Some studies have shown that a growing tumor
burden correlates with aggravating changes in immunity.
Numerous factors are involved in regulating host immu-
nity. Of critical importance are the absolute and relative
proportions of lymphocytes and NK cells, and the func-
tional balance between T-helper type 1 (Th1) and type 2
(Th2) lymphocytes. However, little is known about the
relationship between immunocompetence and the
growth of tongue squamous cell carcinoma induced by
4NQO. Recent views of immunity encouraged us to per-
form a multiparametric immunological assessment of a
rat tongue cancer model, to evaluate its relationship to
tumor progression and immune function, and to observe
the effect of "Shenyang" prescription on immune func-
tion.
Methods
Animals and application of 4NQO
4NQO was obtained as a powder (Sigma, USA) and dis-
solved in water to a final concentration of 0.02 g/l. This
low concentration of 4NQO consistently induced oral
SCC in earlier rodent studies [8,9]. Eighty Sprague-Dawley
(SD) male rats, aged 6–7 weeks, were fed 4NQO in their
drinking water for 36 weeks. During induction, two rats
were sacrificed under general anesthesia at the 6th, 12th,
18th, 24th and 30th weeks for pathological examination.
Another 20 SD rats received pure water (control group).
Experimental Animal Administrative Committee of
Shanghai granted ethical approval for the animal experi-
ments.
Determination of immune function in the rat groups
At the end of the 36th week, ten rats had been sacrificed
for pathological examination and nine had no tumors or
had died during application of the carcinogen. To deter-
mine the relationship between immune function and the
progress of carcinogenesis induced by 4NQO, abnormali-
ties of immune function were tested in the 61 surviving
rats. The oral cavities of these rats were examined under
general anesthesia and the animals were divided into
three groups according to tumor diameter. Group A com-
prised 24 rats with tongue mucosal ulcers in which the
longest diameter was less than 2 mm and with no palpa-
ble tumor invasion; group B comprised 21 rats with inva-
sive tumors in which the longest diameter was less than 5
mm; and group C comprised 16 rats with invasive tumors
of diameter greater than 5 mm. The 20 rats in the control
group had normal tongue mucosas.
Treatment and application of "Shenyang" prescription
The 61 rats with oral tumors were divided into 4 groups
by stratified random sampling: "Shenyang" prescription
group I (16 mice), "Shenyang" prescription group II (15
mice), positive controls (15 mice) and negative controls
(15 mice). All the 61 rats had squamous cell carcinoma
with different stage and size. The pathological results had
been confirmed by three pathologists. Each medicated
group has a comparable number of rats with each of the 3
lesions. The "Shenyang" prescription groups I and II
received "Shenyang" as granules. "Shenyang" prescriptionBMC Cancer 2007, 7:40 http://www.biomedcentral.com/1471-2407/7/40
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was produced by Shanghai Third Chinese Medicine Fac-
tory in China. All herbs (Radix codonopsitis, Radix astragali,
Salvia miltiorrhiza and Glossy privet fruit) used in the
present study were provided by Shanghai Herbs Company
(Shanghai, China). Traditional controls on cultivation
and modern technologies on production were used to
ensure that the composition (level of active ingredient)
was stable for each of the 4 components. The percentages
of the 4 components were Radix codonopsitis (30%), Radix
astragali (30%), Salvia miltiorrhiza (10%) and Glossy privet
fruit (30%)[7]. The doses, determined by the conversion
of body surface area proportion, were 1026 mg/100 g
body weight for group I and 256.5 mg/100 g for group II.
The positive controls received 7.6 mg/100 g Acantho-
panax senticoside (Shanghai Xin Yi Jia Hua Pharmaceuti-
cal Company). The doses for "Shenyang" prescription
group II and the positive control were equivalent to
human dosages. We observed the average daily water
intake of each rat from 2 weeks in order to calculate the
concentration of medicine to be administered. The medi-
cine was then dissolved into water at the appropriate con-
centration and administered for 15 days. The negative
controls received distilled water.
Blood sampling
Before and after treatment, femoral vein blood samples
were obtained in sterile heparinized tubes from all rats
under general anesthesia with methoxyflurane vapor. The
serum samples were collected by centrifugation, stored at
-80°C and thawed immediately before the enzyme-linked
immunosorbent assay (ELISA).
Flow cytometry
T lymphocyte subpopulations were quantified by flow
cytometry (FACSCalibur; Becton Dickinson, USA). Sam-
ples were prepared by adding 5 µl of fluorescent mono-
clonal antibodies against CD3, CD4, CD8 and CD161a
(Pharmingen, Becton Dickinson, USA) to 100 µl of
heparinized whole blood. CD3+CD4+ (T helper cells)
and CD3+CD8+ (T suppressor cells) were measured and
natural killer (NK) cells were recognized as CD3-
CD161a+ [10]. Mouse IgG isotype control antibodies
were used to estimate the amount of nonspecific binding.
Cell preparations were left on ice in the dark for 15 min-
utes. Erythrocytes were then lysed once and, after washing
the WBC pellet, the tubes were placed on ice in the dark
until flow cytometric analysis, which was performed on
the same day.
Cytokine assays
The serum samples were thawed immediately before test-
ing. Supernatant cytokine (IFN-γ, TFN-α, IL-2, IL-4 and IL-
10) levels were measured using commercially available
ELISA kits (Pharmingen, Becton Dickinson, USA) [11].
Monoclonal antibodies specific for rat IFN-γ, TFN-α, IL-2,
IL-4 and IL-10 were pre-coated on to microplates. Stand-
ards, controls and samples were pipetted into the wells.
After washing to remove unbound materials, enzyme-
linked polyclonal antibodies specific for rat IFN-γ, TFN-α,
IL-2, IL-4 and IL-10 were added to the wells. After wash-
ing, the substrates were added. The enzyme reactions
yielded blue products that turned yellow when the stop
solutions were added. The absorbance was measured with
an ELISA reader (Biorad, USA) at 450 nm, corrected by the
absorbance at 630 nm, and a standard curve was used.
Samples were assayed in triplicate and the results were
expressed as the average of the three absorbance readings.
The serum cytokines were considered to be positively
expressed when their concentrations were greater than or
equal to the detection limits (15 pg/ml).
Tumors dissection and histological preparation
After phlebotomy, the rats were sacrificed to resect the
tongue tumors. The volumes of all the tumors were meas-
ured by Vernier calipers. Gross lesions were fixed in 10%
buffered formalin, sectioned and stained with hematoxy-
lin and eosin. All slides were reviewed by three patholo-
gists using light microscopes.
Statistical analysis
All data were analyzed using SAS for Windows 98. Results
were expressed as means and standard deviations. Groups
were compared by t-tests for continuous variables. Statis-
tical significance was defined as P < 0.05.
Results
Characteristics of SD rat model
To determine whether 4NQO reproducibly caused a spec-
trum of neoplastic changes in the tongue, 80 SD rats were
treated with 4NQO for 36 weeks; 61 rats with tumors sur-
vived after this period. Ten were sacrificed for pathological
examination during induction. Nine rats had no tumors
or had died of pneumonia or gastroenteritis.
Morphologically, the lesions at the 6th, 12th, 18th, 24th
and 30th weeks that grew in response to 4NQO demon-
strated a series of squamous cell transformations from
normal mucosa (Fig. 1A) through epithelial dysplasia
(Fig. 1B) to squamous cell carcinoma (Fig. 1C). Exposure
to 4NQO caused both gross and microscopic changes in
the tongues. The macroscopic lesions were shown by
microscope to be squamous cell carcinomas.
Cell counts
During the progression of the tumors, rats in the experi-
mental and control groups had different T lymphocyte
subsets and NK cells counts. The results were summarized
in Fig. 2. The numbers of CD3+CD4+ T cells and the
CD4+/CD8+ ratios were consistently lower in groups A, B
and C than in the control group (P  < 0.05). TheBMC Cancer 2007, 7:40 http://www.biomedcentral.com/1471-2407/7/40
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CD3+CD4+ T lymphocyte counts were significantly lower
in group C than in groups A or B (P < 0.05), but the per-
centages in groups A and B were comparable (P > 0.05).
In addition, the NK cell counts were similar in group A
and control (P > 0.05), but as the lesion enlarged, there
were statistically significant differences among groups B,
C and control (P < 0.05).
Medication produced differences in cells counts, and Fig.
3 shows the results. The percentages of CD3+CD4+ T lym-
phocytes were significantly higher after medication than
before in "Shenyang" prescription group I and II as well as
in the positive controls (P < 0.05). So were the CD4+/
CD8+ ratios in all medicated groups. However, the per-
centages of CD3+CD8+ T lymphocytes were significantly
reduced after medication in all groups except the negative
controls (P < 0.05). The NK cell counts were significantly
increased after medication in "Shenyang" prescription
group I and decreased in the negative controls (P < 0.05).
Th1 and Th2 type cytokine production
Fig. 4 summarized the changes in cytokine production as
the tumor progressed. Serum IFN-γ decreased gradually
and was significantly lower in groups B and C than in the
control group (P < 0.05). The IL-2 concentration in the
control group was 24.13 ± 15.12 pg/ml, but below 15 pg/
ml in groups A and C. Hence, there were significant differ-
ences between each tumor group and the control group (P
< 0.05). Although there was a tendency for IL-4 and IL-10
concentrations to increase, the IL-4 values were statisti-
cally similar in all groups (P > 0.05) while IL-10 produc-
tion differed significantly in each group (P < 0.05). The
cytokine levels did not vary significantly among the tumor
groups at different stages of development of the lesions.
The effect of medication was shown in Fig. 5. The serum
concentrations of TFN-α and IL-2 increased significantly
after medication in "Shenyang" prescription groups I and
II (P < 0.05). IL-4 decreased significantly in "Shenyang"
prescription group I than group II (P < 0.05). The IL-10
values were very significantly lower in both "Shenyang"
prescription groups after medication (P  < 0.01), while
they increased significantly in the negative controls (P <
0.01).
Discussion
Malignant transformation of the oral mucosa is a compli-
cated multi-step and multi-factorial process that is only
partly understood. To develop a new strategy for treating
oral SCC, it is important to understand the progression of
Both gross and microscopic changes in SD rats' tongues mucosas Figure 1
Both gross and microscopic changes in SD rats' tongues mucosas. A. Normal mucosa of tongue base at 6th week 
(gross observation and HE ×200); B. Epithelial dysplasia of tongue base at 24th week (gross observation and HE ×200); C. Squa-
mous cell carcinoma of tongue base at 36th week (gross observation and HE ×200). T represents tongue.BMC Cancer 2007, 7:40 http://www.biomedcentral.com/1471-2407/7/40
Page 5 of 9
(page number not for citation purposes)
Comparison of peripheral lymphocyte subsets pre- and post-administering "Shenyang" prescription Figure 3
Comparison of peripheral lymphocyte subsets pre- and post-administering "Shenyang" prescription. T lym-
phocyte subpopulations were quantitated by flow cytometry. Samples were prepared by adding 5 µl of fluorescent monoclonal 
antibody of CD3, CD4, CD8 and CD161a to 100 µl of heparinized whole blood. CD3+CD4+ (T helper cell) and CD3+CD8+ 
(T suppressor cells) were measured and natural killer (NK) was recognized as CD3-CD161a+. Values (except for CD4+/
CD8+) represent percentage (%). Data were expressed as averages and SD. * means statistic difference (P < 0.05) between 
pre- and post-administering "Shenyang"; I means "Shenyang" prescription group I; II means "Shenyang" prescription group II; PC 
means positive control group; NC means negative control group.
Alteration of peripheral lymphocyte subsets and NK cells with tumor progression Figure 2
Alteration of peripheral lymphocyte subsets and NK cells with tumor progression. T lymphocyte subpopulations 
were quantitated by flow cytometry. Samples were prepared by adding 5 µl of fluorescent monoclonal antibody of CD3, CD4, 
CD8 and CD161a to 100 µl of heparinized whole blood. CD3+CD4+ (T helper cell) and CD3+CD8+ (T suppressor cells) 
were measured and natural killer (NK) was recognized as CD3-CD161a+. Values (except for CD4+/CD8+) represent per-
centage (%). Data are expressed as averages and SD. * means compared with control group, P < 0.05. # means compared with 
group A, P < 0.05. $ means compared with group B, P < 0.05.BMC Cancer 2007, 7:40 http://www.biomedcentral.com/1471-2407/7/40
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the tumor. To date, however, relevant human and rodent
models have been quite limited in number and character-
ization remains unsatisfactory. Oral cancer can be
induced by topical application of the water-soluble car-
cinogen 4NQO and the level of DNA damage is directly
related to the severity of the histological changes [12].
Tang et al. [13] showed that 4NQO changed the expres-
sion patterns of the intermediate filament proteins
keratin14 (K14) and K1. K14 was expressed in the epithe-
lial suprabasal layers in addition to the basal layer. More-
over, more bromodeoxyuridine was found in the tongue
epithelia. Expression of the cell cycle inhibitor p16
decreased, whereas epidermal growth factor receptor
expression increased in the tongue.
4NQO-induced lesions appear to be a good model for
oral cavity carcinogenesis [14]. Premalignant and malig-
nant changes following 4NQO application are local and
occur in the setting of morphologically normal mucosa.
No tumors were observed in the digestive tract (including
the stomach, intestine and colon) or in the lungs or livers
of the 4-NQO-treated rats. This indicates that the rat
model of 4NQO-induced oral carcinogenesis simulates
aspects of human oral cavity carcinogenesis.
The major disadvantage of the rodent 4NQO model is the
long time required for carcinogenesis. The experimental
period is more than 40 weeks. The other disadvantage is
the relatively high mortality. In this study, 6 rats died of
pneumonia or gastroenteritis. A low concentration (0.02
g/l) of 4NQO was used to induce the oral cancer. The
deaths of the rats were not associated with hyperkeratotic
changes in the stomach [15] and subsequent malnutrition
or cumulative toxicity from 4NQO [16].
The results of this study support the concept that host
immunity is implicated in the regulation and progression
of malignant disease. Patients bearing SCCs usually show
systemic immune suppression. This suppression can be
measured as a change in numbers of T lymphocytes and
NK cells [17,18]. There are scattered data on lymphocyte
subsets and immune responses in rat models with SCCs.
One recent report suggested that when 4NQO was applied
to BALB/c mouse tongues, the growing tumor affected the
Alteration of peripheral cytokines with tumor progression Figure 4
Alteration of peripheral cytokines with tumor progression. The serum samples' supernatant cytokines (IFN-γ, TFN-α, 
IL-2, IL-4 and IL-10) levels were measured with commercially available ELISA kits. Data were expressed as averages and SD. * 
means compared with control group, P < 0.05. # means compared with group A, P < 0.05. $ means compared with group B, P 
< 0.05.BMC Cancer 2007, 7:40 http://www.biomedcentral.com/1471-2407/7/40
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immune response around the tumor and systemically
[19]. Moreover, measures to improve immunological sta-
tus may enhance the body's ability to eliminate tumor
cells after conventional therapy and improve the survival
rate. Clinical research has confirmed that "Shenyang" can
improve the survival rate of OSCC patients [7]. To obtain
normal control values, 20 healthy SD rats were selected in
our study. The results demonstrated significant changes in
T lymphocyte subsets and NK cells counts, a decreasing
ratio of CD4+ to CD8+ T lymphocytes, down-regulation
of the Th1 type immune response and up-regulation of
Th2 type lymphocyte function as the tumor progressed,
and these changes were reversed by application of "Shen-
yang".
T lymphocytes are known to be intimately involved in
anti-tumor immune responses. T cells can affect tumor
cells directly, or can act indirectly via the production of
cytokines that amplify cytotoxic T lymphocyte (CTL)
responses or activate NK cells and macrophages. Various
experimental studies have outlined the critical role of
CD4+ and CD8+ T cells and NK cells in mediating anti-
tumor immunity [20-23]. In agreement with other
reports, we observed overall fluctuating differences in the
relative proportion of CD4+ and CD8+ T cells between
the abnormal and normal groups. A persistently lower
CD4+/CD8+ ratio and proportion of NK (CD161a+) cells
has been described in advanced lesions. The present study
confirms the decrease in the CD4+/CD8+ ratio with
increasing tumor burden. This relationship appeared to
result mainly from a decrease in CD4+ T cells and an
increase in CD8+ T cells, especially in group B, as the
tumor progressed.
Many investigators have noted deficient cell-mediated
immunity in advanced cancer patients. The current study
emphasizes that the proportions and functions of immu-
noregulatory cells tend to correlate with the stage of
malignancy [24]. We explain the decreasing CD4+/CD8+
ratio as predominantly due to a decrease of CD4+ T cells
as the tumor progresses. Watson et al [25] found that in
tumor-bearing mice, aberrant antigen presentation prefer-
Comparison of peripheral cytokines pre- and post-administering "Shenyang" prescription Figure 5
Comparison of peripheral cytokines pre- and post-administering "Shenyang" prescription. The serum samples' 
supernatant cytokines (IFN-γ, TFN-α, IL-2, IL-4 and IL-10) levels were measured with commercially available ELISA kits. Data 
are expressed as averages and SD. * means statistic difference (P < 0.05) between pre- and post-administering "Shenyang"; I 
means "Shenyang" prescription group I; II means "Shenyang" prescription group II; PC means positive control group; NC means 
negative control group.BMC Cancer 2007, 7:40 http://www.biomedcentral.com/1471-2407/7/40
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entially expanded CD8+ T cells (but not CD4+ cells),
which failed as effectors of cytotoxicity against tumor
cells; instead, they acted to down-regulate further immune
responses to tumor-associated antigens.
On the other hand, the results also showed that the num-
bers of CD4+ T cells and the CD4+/CD8+ ratio increased
after application of "Shenyang" and Acanthopanax senti-
coside(AS), while the numbers of CD8+ cells decreased
significantly. This indicates that "Shenyang" and AS coun-
ter the disordering of T lymphocyte subsets and improve
the body's immunity. We also found that the application
of 'Shenyang" increased the number of NK cells, while AS
did not. Tumor cells rely on the environment for angio-
genesis. The interplay between them depends mainly on
cytokine secretions [26-28]. The T-helper cytokine profile
has been implicated in coordinating the events that
potentially result in protective host immunity. Lathers et
al [29] demonstrated aberrant cytokine expression in the
plasma of patients with more advanced squamous cell
carcinoma of the head and neck. In this present study AS
was used positive herb for regulating host immunity. By
now some studies reported that AS can regulate the cellu-
lar immunity and factor, indicating that AS can be used as
an assistant drug to regulate the function of immunity in
the patients with cancers [30-32].
Agarwal et al [33] found that the development of oral SCC
led to polarization of cytokine expression, which became
skewed towards the Th1-like response in early stages,
while an increasing tumor load skewed it toward a Th2-
like response. Studies to define the balance between Th1
and Th2 immune responses in human cancer are just
emerging. Our model simulates this progression. Th1-
dominant immunity appears critical for inducing anti-
tumor cellular immunity in mice [34]. Compared with the
control group, SD rats with advancing lesions had down-
regulated Th1-type and up-regulated Th2-type cytokine
production, which implies a shift from Th1 to Th2. Others
have found a normal Th2-type response, but in contrast to
our study, in combination with Th1 deficiency [35],
whereas van Sandick et al [36] reported that cancer
patients demonstrated a shift in the Th1/Th2 balance in
favor of Th1. Our study also showed that "Shenyang"
induced an up-regulation of Th1-type and a down-regula-
tion of Th2-type cytokines, which is a possible mecha-
nism for improving cellular immune function. The
discrepancies may stem to some extent from the variety of
techniques used for cytokine measurement. In this study,
the ability of T cells to produce cytokines was assessed by
ELISA.
Conclusion
Our results showed that 4NQO is a suitable carcinogen for
inducing squamous cell carcinoma in the tongue of SD
rat. SD rats with SCCs had decreased CD4+/CD8+ ratios,
which were associated with a greater tumor load. An
abundance of suppressive CD8+ T cell may be induced by
the tumor itself, or at least help the tumor to enlarge. A
shift in the Th1/Th2 balance is caused by down-regulation
of Th1-type and up-regulation of Th2-type cytokines. The
rats with 4NQO-induced lesions are good models for
exploring oral cavity carcinogenesis and for assessing the
effect of anticancer agent on immunity. The disturbance
of immune function in 4NQO-induced oral cancer rats
can be reversed by administering "Shenyang" prescrip-
tion. These data lead us to propose that immunity against
malignant tumors is perturbed as the tumor progresses,
and that the anticancer function of "Shenyang" prescrip-
tion is underpinned by the improvement of immune
function.
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